Companies

approved · Medical imaging

High7/7warningRaise Risk

5moCRITICAL

approved$2.1B

Neuren Pharmaceuticals

NEU

Trofinetide (DAYBUE) · Rett syndrome

Antisense oligonucleotide

approved · Neurology

High5/5

—

phase 1 2$1.6B

PYC Therapeutics

PYC

VP-001 · Retinitis pigmentosa type 11

phase 1 2 · RNA therapeutics

High5/5

26moSTABLE

Raise Risk$1.1B

Anteris Technologies Global Corp

AVR

DurAVR THV · Aortic stenosis (TAVR / valve-in-valve)

phase 3 · Cardiac

High4/4warningRaise Risk

1moCRITICAL

CF Positive$904M

Nanosonics

NAN

Trophon2 · Ultrasound probe disinfection

approved · Infection prevention

CF+Cash Flow Positive

phase 3$890M

Clarity Pharmaceuticals

CU6

SAR-bisPSMA · Metastatic prostate cancer imaging

PSMA radioligand

phase 3 · Radiopharmaceuticals

1/1hit

27moSTABLE

CF Positive$599M

PolyNovo

PNV

NovoSorb BTM · Burns / complex wounds

Wound Care Biologic

approved · Wound care

1/1hit

CF+Cash Flow Positive

Raise Risk$379M

Racura Oncology

RAC

Bisantrene · Liposarcoma

phase 2 · Oncology

High7/7warningRaise Risk

2moCRITICAL

phase 2$336M

Starpharma

SPL

DEP cabazitaxel · Solid tumours

phase 2 · Drug delivery

High6/6

10moCAUTION

approved$315M

Pacific Edge

PEB

Cxbladder Triage · bladder cancer

approved · Oncology

High7/7

—

approved$508M

Clinuvel Pharmaceuticals Limited

CUV

SCENESSE (afamelanotide) · Erythropoietic Protoporphyria (EPP)

approved · Rare Disease

High3/3

—

approved$194M

Orthocell

OCC

CelGro · Tendon Repair

Regenerative Biologic

approved · Orthobiologics

1/1hit

8moCAUTION

CF Positive$194M

Aroa Biosurgery

ARX

Myriad Matrix · Surgical soft tissue repair

Wound Care Biologic

approved · Wound care

CF+Cash Flow Positive

Raise Risk$154M

Actinogen Medical

ACW

Xanamem · Alzheimer disease

phase 2 · Neurology

High3/3warningRaise Risk

3moCRITICAL

phase 3$142M

Emvision Medical Devices

EMV

emu · intracranial hemorrhage (stroke)

Microwave imaging device

phase 3 · Neurology

2/2hit

40moSTABLE

phase 2$131M

Nyrada

NYR

Xolatryp · STEMI reperfusion injury

Synthetic polymer antibiotic

phase 2 · Cardiovascular / Neurology

High4/4

23moSTABLE

phase 3$150M

Dimerix

DXB

DMX-200 · Focal Segmental Glomerulosclerosis (FSGS)

Gpcr Modulator

phase 3 · Renal disease

High3/3

7moCAUTION

Raise Risk$117M

Recce Pharmaceuticals

RCE

RECCE 327 · Bacterial infections / sepsis

preclinical · Infectious disease

High7/7warningRaise Risk

4moCRITICAL

phase 2$120M

Island Pharmaceuticals

ILA

ISLA-101 (fenretinide) · Dengue

phase 2 · Infectious disease

High6/6

32moSTABLE

CF Positive$95M

Prescient Therapeutics

PTX

PTX-100 · cutaneous T-cell lymphoma

Polysaccharide therapeutic

phase 2 · Oncology

CF+Cash Flow Positive

Raise Risk$84M

Paradigm Biopharmaceuticals Limited

PAR

iPPS · Osteoarthritis (OA)

phase 3 · Rare Disease

High4/4warningRaise Risk

3moCRITICAL

phase 3$126M

EBR Systems

EBRDA

WiSE CRT · Heart failure / CRT

Cardiac pacing device

phase 3 · Cardiac

1/1hit

12moADEQUATE

Raise Risk$67M

Anteotech

ADO

AnteoBind · Diagnostics conjugation platform

approved · Diagnostics

High3/3warningRaise Risk

3moCRITICAL

approved$71M

Cyclopharm

CYC

Technegas · Lung ventilation imaging (nuclear medicine)

approved · Diagnostics

1/1hit

—

phase 1$77M

Arovella Therapeutics

ALA

ALA-101 · B-cell lymphomas and leukaemias

Allogeneic CD19 CAR-iNKT

phase 1 · Oncology

2/2hit

—

phase 1 2$72M

Amplia Therapeutics

ATX

AMP945 · Pancreatic cancer

Kinase Inhibitor

phase 1 2 · Oncology

1/1hit

24moSTABLE

phase 2$49M

Syntara

SNT

SNT-5505 (amsulostat) · Myelofibrosis

Kinase Inhibitor

phase 2 · Haematology

High4/4

17moADEQUATE

Raise Risk$60M

Botanix Pharmaceuticals

BOT

SOFDRA (sofpironium) · Primary axillary hyperhidrosis

approved · Dermatology

High4/4warningRaise Risk

3moCRITICAL

Raise Risk$43M

Imugene

IMU

HER-Vaxx · Gastric cancer

Cancer vaccine

phase 2 · Oncology

High6/6warningRaise Risk

2moCRITICAL

CF Positive$55M

Medical Developments International

MVP

Penthrox · acute trauma pain (adult)

Ion Channel Modulator

approved · Pain management

CF+Cash Flow Positive

Raise Risk$28M

Noxopharm

NOX

Veyonda (idronoxil) · Metastatic castration-resistant prostate cancer

phase 1 2 · Oncology

High5/5warningRaise Risk

1moCRITICAL

Raise Risk$29M

Bcal Diagnostics

BDX

BCALMarker · Breast cancer (early detection)

preclinical · Oncology

2/2hitwarningRaise Risk

3moCRITICAL

Raise Risk$45M

Radiopharm Theranostics

RAD

RAD 204 · Prostate cancer PSMA theranostics

PSMA radioligand

phase 1 · Radiopharmaceuticals

High4/4warningRaise Risk

4moCRITICAL

approved$28M

Proteomics International Laboratories Ltd

PIQ

PromarkerD · diabetic kidney disease (type 2)

approved · Diagnostics

2/2hit

7moCAUTION

CF Positive$25M

Resonance Health Limited

RHT

HepaFatSmart · liver fat assessment (NAFLD/MASLD)

approved · Medical Technology

CF+Cash Flow Positive

preclinical$28M

Inoviq

IIQ

EXO-NET · Cancer diagnostics (multiple)

preclinical · Oncology

11moCAUTION

preclinical$22M

Neuroscientific Biopharmaceuticals

NSB

EmtinB · Alzheimer's disease / MND

preclinical · Neurology

42moSTABLE

phase 2$20M

Argenica Therapeutics Limited

AGN

ARG-007 · acute ischaemic stroke

phase 2 · Neurology

High3/3

12moADEQUATE

CF Positive$15M

IDT Australia

IDT

Radiopharmaceutical CDMO · Contract radiopharmaceutical manufacturing

Other

approved · Radiopharmaceuticals

CF+Cash Flow Positive

Raise Risk$11M

Adalta

1AD

AD-214 · Idiopathic pulmonary fibrosis (IPF)

Fc Fusion Protein

phase 1 · Fibrosis

High5/5warningRaise Risk

1moCRITICAL

phase 1$13M

Patrys

PAB

PAT-DX1 · Solid tumours (deoxymab)

Monoclonal antibody

phase 1 · Oncology

High3/3

13moADEQUATE

approved$20M

ImpediMed Limited

IPD

SOZO / BodyComp · Body composition analysis

approved · Oncology

High7/7

9moCAUTION

Raise Risk$7M

Acrux

ACR

Lenzetto · menopausal hot flushes

approved · Dermatology

High6/6warningRaise Risk

2moCRITICAL

phase 2$7M

Biotron

BIT

BIT225 · HIV-1 reservoir eradication

Ion Channel Modulator

phase 2 · Infectious disease

2/2hit

21moSTABLE

phase 3$9M

Invex Therapeutics

IXC

Presendin · Idiopathic intracranial hypertension

Hyperimmune bovine colostrum (oral)

phase 3 · Neurology

24moSTABLE

approved$12M

Immuron

IMC

Travelan · travellers diarrhoea prevention

approved · Gastrointestinal

23moSTABLE

Raise Risk$3M

Cynata Therapeutics

CYP

CYP-004 · knee osteoarthritis

Mesenchymal Stem Cell

phase 3 · Cell therapy

High7/7warningRaise Risk

2moCRITICAL

phase 1$4M

Percheron Therapeutics

PER

PRCH-1 · Solid tumours (ATR inhibitor)

Kinase Inhibitor

phase 1 · Oncology

1/1hit

7moCAUTION

Raise Risk$2M

Chimeric Therapeutics

CHM

CDH17 CAR-T · GI cancers

Autologous CDH17 CAR-T

phase 1 2 · Cell therapy

High4/4warningRaise Risk

2moCRITICAL

phase 3$5M

Tissue Repair

TRP

CACIPLIQ20 (RGTA) · Post-surgical scars

Regenerative Biologic

phase 3 · Dermatology

12moADEQUATE

phase 2$18M

Opthea

OPT

Sozinibercept · Wet AMD

Fc Fusion Protein

phase 2 · Ophthalmology

High3/3

64moSTABLE

CF Positive$71M

Immutep Limited

IMM

eftilagimod alpha (efti) · metastatic breast cancer

Fc Fusion Protein

phase 2 3 · Oncology

2/2hit

CF+Cash Flow Positive

Active—

Neurotech International

NTI

Biotech company at clinical stage.

discovery

High5/5

—

Active—

Incannex Healthcare

ICG

Biotech company at clinical stage.

discovery

—

Active—

PharmAust

PAA

Biotech company at clinical stage.

discovery

—

Active—

Recce Pharmaceuticals

REC

Biotech company at clinical stage.

discovery

2/2hit

—

CF Positive$39.8B

ResMed

RMD

AirSense 11 · Obstructive sleep apnea (CPAP)

approved · Sleep & respiratory

1/1hit

CF+Cash Flow Positive

CF Positive$19.2B

Fisher & Paykel Healthcare

FPH

Optiflow · Nasal high flow oxygen therapy

approved · Sleep & respiratory

1/1hit

CF+Cash Flow Positive

CF Positive$16.7B

Pro Medicus

PME

Visage 7 · Diagnostic imaging platform (radiology PACS)

approved · Medical imaging

High6/6

CF+Cash Flow Positive

CF Positive$10.4B

Sonic Healthcare

SHL

Radiology services · Diagnostic imaging services

approved · Pathology

CF+Cash Flow Positive

CF Positive$7.3B

Cochlear Limited

COH

Osia 2 System · Conductive/mixed hearing loss (bone conduction)

approved · Hearing implants

CF+Cash Flow Positive

phase 2$5.9B

Alterity Therapeutics

ATH

ATH434 · multiple system atrophy

phase 2 · Neurology

High5/5

—

approved$675M

Imricor Medical Systems

IMR

Vision-MR Deflectable Sheath · MRI-guided cardiac catheter navigation

approved · Cardiac

High4/4

—

CF Positive$408M

Cogstate

CGS

Cogstate Brief Battery · Cognitive impairment detection (clinical trials)

approved · Diagnostics

High9/9

CF+Cash Flow Positive

approved$256M

Healius

HLS

Montserrat Day Hospitals · Day hospital / procedural services

Other

approved · Medical imaging

—

approved$220M

Mayne Pharma Group

MYX

NEXTSTELLIS · Oral contraception (estetrol-based)

approved · Specialty pharmaceuticals

High3/3

—

approved$195M

AVITA Medical

AVH

RECELL System · full-thickness skin defects

approved · Wound care

2/2hit

—

approved$103M

SomnoMed

SOM

SomnoDent Avant · Obstructive sleep apnea (oral appliance)

approved · Sleep & respiratory

—

approved$102M

Lumos Diagnostics

LDX

FebriDx · Acute respiratory infections